logo
Plus   Neg
Share
Email

Johnson & Johnson Seeks Emergency WHO Nod For Single-dose COVID-19 Vaccine

Johnson & Johnson (JNJ) said Friday that it has submitted for Emergency Use Listing to the World Health Organization or WHO for the investigational single-dose Janssen COVID-19 vaccine candidate.

The company said that the Emergency Use Listing process expedites access to products in many countries around the world and is also a prerequisite to supply vaccines to the new COVAX Facility, a global mechanism for pooled procurement and distribution of COVID-19 vaccines in 190 participating countries, including 92 lower-income countries.

Johnson & Johnson filed for emergency use authorization of its single-dose COVID-19 vaccine candidate in the United States on February 4, 2021. It also submitted a Conditional Marketing Authorisation Application in the European Union on February 15, 2021. In addition, rolling submissions for the investigational single-dose COVID-19 vaccine have been initiated in several countries worldwide.

Moderna and Pfizer vaccines, which are now being distributed in the US, are administered as two doses, and the Pfizer vaccine requires ultra-cold storage.

In a phase III trial, dubbed ENSEMBLE, which included participants from different geographies and including those infected with an emerging viral variant, Janssen's COVID-19 vaccine candidate was 66% effective overall in preventing moderate to severe COVID-19, 28 days after vaccination.

The onset of protection was observed as early as day 14. The level of protection against moderate to severe COVID-19 infection was 72% in the United States, 66% in Latin America and 57% in South Africa, 28 days post-vaccination, according to Johnson & Johnson.

If authorized, Johnson & Johnson's investigational single-dose vaccine is estimated to remain stable for two years at minus 20 degree celsius, at least three months of which can be stored in most standard refrigerators at temperatures of 2 degree Celsius to 8 degree Celsius.

In December 2020, Johnson & Johnson entered into an agreement in principle with Gavi, the Vaccine Alliance in support of the COVAX Facility. They expect to enter into an Advance Purchase Agreement that would provide up to 500 million doses of the Janssen vaccine to COVAX through 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Pharmacy, the retail division of CVS Health, announced the availability of three over-the-counter or OTC COVID-19 testing options in stores and online. With these new-to-market home tests, customers will get access to convenient testing that can be conducted at home. The tests include the Ellume COVID-19 Home Test, the Abbott BinaxNOW COVID-19 Antigen Self Test and the Pixel by Labcorp PCR Tes United Airlines is adding three new flights to Croatia, Greece and Iceland, which are starting to reopen to vaccinated visitors. The move would give travelers more options for summer travel by flying direct to these countries. Last month's searches on United.com for flights to Croatia, Greece and Iceland were up 61 percent. Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden.
Follow RTT